The American Society of Medical Oncology (ASCO) convention is the place the worldwide most cancers care neighborhood collect to debate key developments in most cancers analysis and coverage. This 12 months, it was held from Might 29 to June 2, in Chicago, Illinois. Labiotech heard from specialists concerning the main traits and highlights of ASCO 2026.
Revolution Medication’s daraxonrasib: a win for pancreatic most cancers care
Lauded as a “recreation changer,” Revolution Medication’s daraxonrasib was discovered to double survival time in sufferers with pancreatic most cancers in one of many greatest breakthroughs in years. The once-daily tablet was evaluated in a section 3 examine the place 500 sufferers with pancreatic ductal adenocarcinoma, a really aggressive and hard-to-treat most cancers, the place sufferers have been both administered daraxonrasib, a RAS inhibitor, or chemotherapy. Daraxonrasib works by turning off the KRAS protein, which, when mutated, results in tumor cell development.
Hitting all main and secondary endpoints, the drug led to a 60% discount within the threat of demise. Plus, a 33.2% goal response fee was noticed in sufferers on the remedy in comparison with 11.8% with chemotherapy in sufferers with a RAS G12 mutation and a 31.6% with daraxonrasib in comparison with 11.2% with chemotherapy within the intent-to-treat inhabitants, which included sufferers who might or might not have had a RAS tumor.
This represents a “main milestone,” in keeping with Brian Wolpin, principal investigator for the daraxonrasib trial.
“For a lot of sufferers, second line chemotherapy gives modest advantages, and new remedies delivering extra sturdy tumor management have been urgently wanted,” he mentioned in a press launch. “These outcomes will change how scientists, clinicians, and sufferers take into consideration therapy for pancreatic most cancers, and assist a brand new paradigm the place RAS(ON) inhibition enters normal of take care of sufferers with beforehand handled metastatic pancreatic adenocarcinoma.”
Massive pharmas BioNTech, Bristol Myers Squibb, Boehringer Ingelheim see therapeutic progress
In the meantime, large pharmas had some large reveals at ASCO. A much-awaited readout was of BioNTech and Bristol Myers Squibb’s PD-(L)1xVEGF bispecific antibody pumitamig in section 2/3 trials in non-small cell lung most cancers (NSCLC). Furthermore, the knowledge confirmed encouraging anti-tumor exercise, with excessive response charges noticed in each non-squamous and squamous NSCLC and at every PD-L1 expression stage.
Pumitamig is not like different checkpoint inhibitors, in keeping with Solange Peters, lead investigator and director of Oncology on the College Hospital of Lausanne in Switzerland.
“Regardless of vital immuno-oncology advances within the therapy of non-small cell lung most cancers, most superior ailments relapse on or after a PD-(L)1 checkpoint inhibitor therapy, indicating that focusing on this immunologic pathway alone is inadequate to realize sturdy responses,” mentioned Peters. “I’m inspired by the efficacy sign with this bispecific strategy, exhibiting sturdy responses throughout subtypes and PD-L1 ranges, supporting the continued investigation of pumitamig and its potential to ship improved outcomes for a broad vary of sufferers with NSCLC.”
German pharma big Boehringer Ingelheim’s tyrosine kinase inhibitor was additionally evaluated in an NSCLC examine, and it confirmed “encouraging early alerts.” Sufferers with HER-positive NSCLC reported enhancements in every week of being handled with pumitamig.
Furthermore, in sufferers with HER2-positive mCRC, the ORR was 42% and the illness management fee was 95%, in keeping with a pooled evaluation from its Beamion LUNG-1 trial and the section 2 Beamion PANTUMOR-1 trial.
“The early knowledge for zongertinib underscore its potential throughout a broader vary of HER2-altered stable tumors past lung most cancers. Preliminary findings from ongoing research, together with Beamion BCGC-1 and PANTUMOR-1, counsel encouraging scientific exercise and a manageable security profile, each as a monotherapy and together with different brokers. Whereas these outcomes are preliminary, they assist the continued scientific investigation of zongertinib throughout a number of HER2-driven cancers, together with colorectal, gastroesophageal, and breast tumors,” Itziar Canamasas, world head of Oncology at Boehringer Ingelheim instructed Labiotech.
Johnson & Johnson’s Rybrevant Faspro to tackle head and neck cancers
Within the head and neck most cancers therapeutics area, Johnson & Johnson’s Rybrevant Faspro was below evaluate. Rybrevant Faspro was accepted by the U.S. Meals and Drug Administration (FDA) for non-small cell lung most cancers in 2025 and is at present being studied throughout different indications together with head and neck most cancers and colorectal most cancers.
Now, it’s chasing approval to deal with head and neck cancers, having snagged Breakthrough Remedy designation for Rybrevant Faspro to focus on the indication in February. The OrigAMI-4 knowledge introduced at ASCO 2026 indicated deep, sturdy responses in a affected person inhabitants with very restricted therapy choices after progressing on each immunotherapy and chemotherapy.
Rybrevant Faspro achieved a 42% general response fee, with greater than one-third of responders reaching an entire response. It additionally led to tumor shrinkage in nearly all of sufferers, and the median length of response had not but been reached. These responses translated right into a median general survival of 12.5 months, that means sufferers lived greater than a 12 months on common, regardless of having illness that had progressed.
“Roughly 80% of recurrent or metastatic head and neck cancers are pushed by EGFR and MET pathways, making them necessary targets for therapeutic intervention. Rybrevant Faspro is uniquely designed to focus on each pathways concurrently, and the outcomes we’re seeing counsel that strategy might translate into significant scientific profit for sufferers,” mentioned Mark Wildgust, vp of World Medical Affairs Oncology at Johnson & Johnson.
These findings construct on what’s already been seen with Rybrevant Faspro in lung most cancers, and exhibit the potential of a subcutaneous therapy choice in head and neck most cancers. This might make therapy extra manageable for sufferers, and has not beforehand been studied on this setting.
The pharma big can be invested in treating prostate most cancers. “One of many greatest themes in prostate most cancers proper now’s transferring earlier in therapy, earlier than the illness has the prospect to unfold,” mentioned Wildgust. “The PROTEUS examine is a vital instance of treating sufferers earlier in the middle of illness, with the objective of bettering outcomes for these present process curative-intent therapy.”
Sufferers within the examine have been 9 occasions extra prone to have little to no most cancers remaining on the time of surgical procedure, and the routine lowered the chance of metastasis or demise by 20%. There was additionally a significant delay within the want for extra therapy, giving sufferers roughly six years earlier than needing subsequent remedy. As well as, most sufferers skilled testosterone restoration following therapy, sometimes inside about eight months.
“ASCO plenaries are about heralding basic adjustments in most cancers care. The truth that the PROTEUS outcomes have been chosen to open this 12 months’s ASCO plenary session and have been concurrently printed within the New England Journal of Medication speaks to the importance of those knowledge and their potential influence on scientific follow,” mentioned Wildgust.
ADCs and T-cell engagers draw consideration
In addition to, antibody-drug conjugates (ADCs) and T-cell engagers have come fairly far through the years. AbbVie’s Decnupaz was simply accepted by the FDA, making it the primary and solely ADC to deal with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare, extremely aggressive blood most cancers.
“We’re seeing ADCs and T-cell engagers evolve past standalone therapies towards extra exact, built-in therapy methods designed to ship deep and lasting responses, notably for sufferers with difficult-to-treat cancers. That is supported by the scientific rationale to assault tumors from each inside (direct killing) and outdoors (by participating the immune system or altering the TME),” mentioned Eleni Lagkadinou, vp of Oncology Early Improvement at AbbVie.
The American big AbbVie showcased an expansive oncology pipeline at ASCO 2026. The ADC ABBV-969 demonstrated encouraging monotherapy exercise in sufferers with metastatic castration-resistant prostate most cancers (mCRPC), nearly all of whom have exhausted out there therapy choices, with a confirmed goal response fee (ORR) of 45%, PSA50 response fee of 67%, and PSA90 response fee of 30% at energetic dose ranges, Lagkadinou instructed Labiotech.
One other one of its ADCs, ABBV-706, that targets SEZ6, confirmed promising exercise in relapsed/refractory small cell lung most cancers (SCLC), with an ORR of 82% at a dosage of 1.8 mg/kg in section 3 research.
“Early proof of sturdiness, fast tumor shrinkage, and circulating tumor DNA (ctDNA) declines additional assist its organic exercise,” mentioned Lagkadinou.
ABBV-706 together with AbbVie’s monoclonal antibody budigalimab demonstrated encouraging antitumor exercise and sturdy responses within the second-line setting, indicating the compatibility of this strategy with an immunotherapy. The ADC can be being examined together with PD-1 inhibitors.
The corporate additionally introduced knowledge from its trial testing the ADC Temab-A (ABBV-400). It confirmed exercise throughout a number of stable tumors, together with ORRs of 80% in c-Met chosen sufferers with platinum-resistant ovarian most cancers and round 31% in c-Met chosen sufferers with head and neck most cancers, Lagkadinou defined.
As for T-cell engagers, etentamig exhibited “sturdy” section 1b exercise in relapsed/refractory a number of myeloma, together with in sufferers who’ve undergone CAR-T therapy. ORRs of as much as round 64% have been achieved.
“Our work in T‑cell engagers, akin to etentamig, focuses on growing next-generation multispecific therapies that improve efficacy and sturdiness by selectively focusing on tumor cells and reworking the immunosuppressive tumor microenvironment, enabling mixture and sequencing approaches, whereas guaranteeing security and an optimized affected person expertise and high quality of life,” mentioned Lagkadinou.
ASCO 2026: Storm Therapeutics and Syndax Prescription drugs unveil scientific knowledge
In the meantime, smaller biotechs unveiled promising knowledge from oncology research too. Like Cambridge-based Storm Therapeutics, whose small molecule STC-15 was discovered to be effectively tolerated, in keeping with interim section 1 knowledge. STC-15 inhibits METTL3, a key RNA methyltransferase concerned in programming stem cells. By inhibiting METTL3, STC-15 interrupts the differentiation and development of sarcomas, which derive from stem cells, finally main to most cancers cell killing by inducing cell cycle arrest, defined Jerry McMahon, chief government officer (CEO) and president of Storm Therapeutics.
“Within the section 1 examine, STC-15 confirmed security and efficacy as a single-agent in a spread of stable tumors. STC-15 is at present being explored in a section 2 examine in chosen sarcomas,” he added.
One other small molecule that was talked about at ASCO 2026 was Syndax Prescription drugs’ revumenib. It was cleared by the FDA to deal with relapsed or refractory acute leukemia in 2024, and now researchers are learning if using the menin inhibitor as upkeep remedy following stem cell transplantation can cut back the chance of relapse and enhance long-term outcomes amongst sufferers with acute myeloid leukemia.
Sufferers on the remedy had a 90% general survival fee after two years, virtually double the speed noticed previous to treating with revumenib. The examine had 24 sufferers.
Whereas the pattern measurement is small, these outcomes are promising and strongly assist additional analysis of revumenib as post-transplant upkeep,” mentioned Ghayas C. Issa, affiliate professor of Leukemia at The College of Texas MD Anderson Most cancers Middle.
In line with Nick Botwood, head of Analysis & Improvement and chief medical officer of Syndax Prescription drugs, the examine outcomes contribute to an space of excessive doctor curiosity and inform additional scientific analysis.
ASCO 2026: radiopharma “shifting from a interval of pleasure” into execution
In the meantime, radiopharmaceuticals are projected to hit $31 billion by 2032, pushed by blockbusters, akin to Pluvicto and Lutathera. Massachusetts-based Ratio Therapeutics is at present recruiting sufferers for its section 1/2 trial of its radiopharma candidate [Ac-225]RTX-2358. John Babich, Ratio’s chief scientific officer (CSO), believes that there’s a lot to look ahead to within the area.
“Radiopharmaceuticals in 2026 are shifting from a interval of pleasure and momentum into what many see as an ‘execution 12 months.’ The trade’s focus is more and more centered on advancing novel targets, strengthening isotope provide reliability, and persevering with to mature the chemistry, manufacturing, and controls (CMC) and manufacturing panorama wanted to assist broader scientific and business improvement,” mentioned Babich.
In addition to, oncolytic viruses are gaining traction. These viruses have been engineered to goal and assault tumors. As most cancers cells have impaired antiviral defenses that make them inclined to an infection, in keeping with the Most cancers Analysis Institute, these viruses might be modified to focus on most cancers with out infecting regular cells. Nevertheless, challenges with supply must be tackled.
“Oncolytic viruses, thus far, have largely been intratumoral remedy. The massive hurdle has been systemic supply, the place the blood’s complement system has traditionally been too giant an impediment to beat. To be able to overcome complement, firms have tried dosing at very excessive ranges, usually dosing the overwhelming majority of a single batch simply to get some virus-on-tumor. This isn’t an economical mode of remedy. As an alternative, they resort to intratumoral dosing, which is commonly tough and costly for inside tumors,” mentioned Mark Bertagnolli, chief working officer of California-based oncolytic virus developer ViroMissile.
At ASCO 2026, the corporate introduced knowledge of its virus IDOV-Protected, which comprises a gene that works to drive necroptosis in sure cancers – micro satellite tv for pc steady colorectal most cancers (MSS CRC) particularly, which accounts for about 85% of all colorectal cancers.
“It is a chilly tumor, so it doesn’t reply to immunotherapy and may be very tough to deal with,” mentioned Bertagnolli.
The virus managed to transform the tumor microenvironment from chilly to sizzling, sensitizing tumors to the triple mixture that’s initiated a number of months later, defined Bertagnolli.
The target response fee was 30% with a median development free survival of 8.7 months in closely pretreated sufferers.
“Our outcomes present that the virus is well-tolerated, with an efficacy sign that warrants a section 2 examine,” he mentioned.
Precision drugs: an evolving area
Lastly, precision drugs was additionally in focus on the summit. The worldwide market measurement of the sector is projected to develop from $109.54 billion in 2026 to $266.63 billion by 2034, exhibiting a compound annual development fee (CAGR) of 11.76% in the course of the forecast interval, in keeping with a report by Fortune Enterprise Insights. James Hamrick, chairman of the Precision Oncology Alliance at Caris Life Sciences, believes that the sphere is turning into dynamic. He defined that it isn’t merely a one-time check at analysis; it’s more and more about monitoring how cancers evolve, detecting resistance, and adapting therapy over time.
“Precision drugs in most cancers has moved from an aspirational idea to a sensible basis of oncology care. In 2026, the query is not whether or not a tumor needs to be molecularly profiled, however how shortly and comprehensively we are able to use that info to information care. Broad molecular testing, together with DNA, RNA, and more and more blood-based approaches, helps clinicians determine actionable alterations, match sufferers to focused therapies or trials, and refine prognosis,” he mentioned.
As ASCO 2026 drew to a detailed yesterday, the analysis introduced on the occasion sign a shift in the direction of focused therapies, with breakthroughs in hard-to-treat most cancers remedies providing new hope to sufferers.
